
India accounts for 6.4% of global zero-dose children in 2024: UN
The new national immunisation coverage data released on Monday by the World Health Organisation (WHO) and UNICEF also highlighted that "India accounted for 49.2% of zero-dose children in South Asia", as per statistics from the Regional Office for South Asia (ROSA).
The term "zero-dose children" refers to those who have not received any routine immunisations, including the first dose of the DTP (diphtheria, tetanus, and pertussis) vaccine. This metric is a critical indicator of access to immunisation services and overall healthcare infrastructure.
The report said India accounted for "6.4% of zero-dose children globally". Every year, WHO and UNICEF release global and national routine immunisation coverage estimates (WUENIC).
Gavi, the Vaccine Alliance, analyses what the 2024 WUENIC data says about the state of immunisation in the 57 low- and lower-middle-income countries it supports.
Gavi said nearly half (4.9 million) of all the 10.2 million zero-dose children in lower-income countries live in five populous nations - Nigeria, DR Congo, India, Pakistan, and Ethiopia.
It pointed out that coverage with the first dose of the DTP vaccine (DTP1) is an important measure that helps the world understand how many zero-dose children still don't have access to life-saving vaccines.
DTP1 coverage stood at 87 per cent in 2024 - nearly recovered from a four percentage point decrease during the COVID-19 pandemic.
"This means there are half a million fewer zero-dose children in lower-income countries in 2024, thanks mainly to targeted efforts in populous countries like India, DR Congo, and Ethiopia," Gavi said.
The report said in 2024, 89 per cent of infants globally -- about 115 million -- received at least one dose of DTP vaccine, and 85 per cent -- roughly 109 million -- completed all three doses.
Compared to 2023, around 171,000 more children received at least one vaccine, and one million more completed the full three-dose DTP series.
While the gains are modest, they signal continued progress by countries working to protect children, even amid growing challenges, the report said.
Still, nearly 20 million infants missed at least one dose of DTP-containing vaccine last year, including 14.3 million "zero-dose" children who never received a single dose of any vaccine.
That's four million more than the 2024 target needed to stay on track with Immunisation Agenda 2030 goals and 1.4 million more than in 2019, the baseline year for measuring progress, the report said.
"Vaccines save lives, allowing individuals, families, communities, economies, and nations to flourish," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
"It's encouraging to see a continued increase in the number of children being vaccinated, although we still have a lot of work to do. Drastic cuts in aid, coupled with misinformation about the safety of vaccines, threaten to unwind decades of progress," he said.
The report noted that children often remain un- or under-vaccinated due to a combination of factors, such as limited access to immunisation services, disrupted supply, conflict and instability, or misinformation about vaccines.
Data from 195 countries show that 131 countries have consistently reached at least 90% of children with the first dose of DTP vaccine since 2019, but there has been no significant movement in expanding this group.
Among the countries that reached less than 90% in 2019, only 17 managed to increase their coverage rates in the past five years. Meanwhile, in 47 countries, progress is stalling or worsening. This includes 22 countries that achieved and surpassed the 90% target in 2019 but have since declined.
The data shows conflict and humanitarian crises can quickly erode vaccination progress.
A quarter of the world's infants live in just 26 countries affected by fragility, conflict, or humanitarian crises, yet they make up half of all unvaccinated children globally.
Concerningly, in half of these countries, the number of unvaccinated children has expanded rapidly from 3.6 million in 2019 to 5.4 million in 2024, underscoring the need for humanitarian responses to include immunisation, the report said
Immunisation coverage in the 57 low-income countries supported by Gavi has improved in the past year, reducing the number of un- and under-vaccinated children by roughly 650,000.
At the same time, signs of slippage are emerging in upper-middle- and high-income countries that have previously maintained at least 90% coverage. Even small declines in immunisation coverage can dramatically raise the risk of disease outbreaks and place additional strain on already overstretched health systems.
"The good news is that we have managed to reach more children with life-saving vaccines. But millions of children remain without protection against
preventable diseases
, and that should worry us all," said UNICEF Executive Director Catherine Russell.
"We must act now with determination to overcome barriers like shrinking health budgets, fragile health systems, along with misinformation and access constraints because of conflicts. No child should die from a disease we know how to prevent," she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hindu
a few seconds ago
- The Hindu
Tiruchi Corporation speeds up construction of urban health centres
In an effort to improve public access to healthcare services, Tiruchi Corporation has expedited the construction of new urban primary health centres (UPHCs) and urban health sub-centres (HSCs) across the city, The move comes in response to increasing public patronage of UPHCs in recent years, particularly during the COVID-19 pandemic, which exposed the urgent need to expand public health infrastructure. Officials said the new centres were expected to ease pressure on existing facilities and offer hassle-free access to essential medical services, particularly for economically weaker sections. Under the National Urban Health Mission (NUHM), the scheme envisions establishing one UPHC for every 50,000 people. With a population of 12 lakh, Tiruchi requires 24 UPHCs to ensure adequate healthcare coverage. At present, the city has 18 UPHCs and 36 health and wellness centres. Several new UPHCs are under construction, while existing centres are being renovated and expanded. A new facility is being built at Panjapur with provision for inpatient facility, consultation rooms, and labs. The centre is aimed at covering low-income groups in the locality. Similarly, new facilities are being constructed at Lakshmi Nagar in Srirangam, Kongu Nagar in Ariyamangalam and Pappakurichi in Kattur at ₹1.20 crore each. New UPHCs are being established at Erikarai Main Road in Subramaniyapuram and Beerangikulam at a cost of ₹1.50 crore each. Construction of additional buildings for the UPHCs is underway in Pappakurichi, Teppakulam, and Beemanagar areas, with an outlay of ₹60 lakh each. Similarly, urban health sub-centres are being established at Thiruvanaikovil, Ariyamangalam, and Khajamalai at a cost of ₹30 lakh each. Meanwhile, urban health sub-centres at K.K. Nagar, Pandamangalam, Rail Nagar, Melur, JJ Nagar, Malai Kovil and Edamalaipattipudur, which were built at a cost of ₹30 lakh each, and additional buildings for the Thennur UPHC are ready for inauguration. 'The construction work is progressing at a brisk pace, and work at several sub-health centres is at finishing stages and is expected to be completed within two months,' said M. Vijay Chandran, City Health Officer. The new centres are being set up in the city under the National Urban Health Mission with financial assistance from the Central and State governments.


Time of India
a few seconds ago
- Time of India
'Is this real or just in my head?': Doctor's haunting testimony on mRNA COVID vaccine shakes Senate
The Senate Homeland Security Committee hears heartbreaking testimonies from victims of alleged mRNA COVID vaccine injuries. A Father, Brian Hooker, revealed his son suffered both a heart attack and was diagnosed with autism after vaccination. The hearing titled "Voices of the Vaccine-Injured" sheds light on stories mainstream media ignored. Watch explosive moments and emotional appeals to lawmakers. Show more Show less
&w=3840&q=100)

Business Standard
4 hours ago
- Business Standard
ICMR invites EoIs for tech transfer to commercialise malaria vaccine
The Indian Council of Medical Research (ICMR) has invited expressions of interest (EoI) from eligible companies and manufacturers to undertake the transfer of technology for commercialisation of an indigenous recombinant multi-stage malaria vaccine candidate named AdFalciVax. The vaccine candidate, being developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), aims to prevent plasmodium falciparum, a parasite which causes severe and fatal malaria, in humans and minimise its community transmission. According to the EoI, ICMR-RMRCBB will also provide expert guidance and technical support for the production of the vaccine in all phases, effectively accelerating its development and commercialisation. The agreement is proposed to be executed on a non-exclusive basis with single or multiple companies to enable wider outreach of the malaria vaccine for societal benefit and public health use. It added that the development may take at least seven years in four stages with each stage having a six-month buffer time. While ICMR would provide technical support through its team of experienced scientists in study planning and product development, the selected company would be responsible for obtaining all the regulatory approvals, starting from research and development (R&D) for product development to its commercialisation. The Council will also have no financial implications unless otherwise specified, however, its institutes would provide support and facilitation to conduct the R&D and clinical studies of new technology in India. The EoI adds that in case of transfer of technology, ICMR is the sole owner of the said technology, including any underlying Intellectual Properties and commercialisation rights. 'In case of collaboration between ICMR and the company for the joint development of the technology/product, the Background Intellectual Property (BGIP) shall always remain the sole and non-exclusive property of the party generating it,' the EoI said. As part of the agreement, the collaborating company will be required to share technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. 'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the medical research body said. According to the World Health Organisation's (WHO) World Malaria Report 2024, India contributes half of all estimated cases in the South East Asia Region, which in turn accounts for 1.5 per cent of the global malaria burden. India currently has access to two WHO-recommended malaria vaccines, Mosquirix and R21/Matrix-M. While the former is manufactured by GlaxoSmithKline (GSK), the latter is manufactured by the Serum Institute of India (SII). Both vaccines are primarily for children in areas with moderate to high malaria transmission. 'Based on preclinical data, AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines,' an official in the know said. The pre-clinical validation of the vaccine candidate was conducted in collaboration with the Indian Council of Medical Research-National Institute of Malaria Research, other constituent institutes of ICMR, and the National Institute of Immunology in Delhi, an autonomous research institute of the Department of Biotechnology.